Cogent Biosciences, Inc. (COGT) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Cogent Biosciences is a clinical-stage biotechnology company focused on precision therapies for genetically defined diseases. The company's primary asset is bezuclastinib (CGT9486), a KIT inhibitor for Systemic Mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST). The company has filed three New Drug Applications (NDAs) with the FDA, with PDUFA target dates in late 2026. Management expects a commercial launch in the U.S. in the second half of 2026 pending approval.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(96.4) million | $(193.8) million | $(145.5) million |
| Operating Expenses | $102.6 million | $206.2 million | $150.5 million |
| Research & Development | $70.8 million | $146.2 million | $125.2 million |
| General & Administrative | $31.8 million | $60.1 million | $25.3 million |
| Interest Income | $7.5 million | $15.1 million | $5.3 million |
| Cash & Marketable Securities | $792.3 million (as of June 30, 2026) | ||
| Convertible Senior Notes (Net) | $223.5 million (Principal: $230.0 million) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2026, increased by $48.2 million compared to the same period in 2025, driven by higher operating expenses.
- R&D Spend: R&D expenses increased by $20.9 million year-over-year (YTD), primarily due to costs supporting late-stage clinical programs (SUMMIT, PEAK, APEX), regulatory activities for bezuclastinib, and pre-approval manufacturing costs.
- G&A Expansion: General and administrative expenses surged by $34.8 million YTD, reflecting investments in commercial readiness, personnel, and infrastructure to support the anticipated 2026 launch.
- Stock-Based Compensation: Total stock-based compensation increased to $34.0 million for the six months ended June 30, 2026, up from $19.7 million in the prior year period.
- Debt Structure: The company issued $230 million in Convertible Senior Notes in November 2025 and fully repaid its previous $50 million Credit Facility using proceeds from the Notes.
Guidance, Outlook, and Risks
- Regulatory Milestones: The FDA has assigned PDUFA target action dates of November 30, 2026 for GIST and December 30, 2026 for Non-Advanced SM. An NDA for Advanced SM was submitted in June 2026.
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($792.3 million), plus $71.4 million in post-quarter ATM proceeds, are sufficient to fund operations into late 2028.
- Capital Raising: The company utilized its At-The-Market (ATM) facility, selling shares for net proceeds of $45.7 million in the first half of 2026 and $71.4 million subsequent to quarter-end. $88.6 million remains available under the ATM agreement as of June 30, 2026.
- Risks: Key risks include the potential for FDA rejection or delay of NDAs, failure to achieve commercial success post-approval, and the need for additional capital if the burn rate exceeds projections or if regulatory approval is delayed.
Investor Verification Checklist
- Regulatory Status: Confirm the status of the three pending NDAs (NonAdvSM, AdvSM, GIST) and any FDA requests for additional information.
- Cash Runway: Verify the burn rate against the $792.3 million cash balance to ensure the "late 2028" runway remains valid given the increased G&A spend.
- Commercial Readiness: Assess the progress of the internal commercial organization build-out and manufacturing capacity for a potential H2 2026 launch.
- Dilution Risk: Monitor the usage of the remaining $88.6 million ATM capacity and the potential conversion of the $230 million Convertible Senior Notes (conversion price ~$44.95).
- Milestone Payments: Track the $15.0 million in potential regulatory milestone payments due to Plexxikon within the next 12 months.